Thyrocare Q4FY26: Revenue up 20% to ₹223.95 Cr, PAT surges 128% to ₹48.70 Cr
Thyrocare Technologies reported Q4 FY26 consolidated revenue of ₹223.95 crore, up 20% YoY. PAT surged 128% to ₹48.70 crore, and EBITDA grew 31% to ₹75.09 crore. The company processed 59.0 million tests, a 29% YoY increase. For FY26, revenue reached ₹829.04 crore (up 21% YoY), with PAT at ₹162.85 crore (up 81% YoY).
The significant increase in revenue and profit, coupled with strategic expansion into new diagnostic areas like genomics, indicates a positive and material impact on the company's performance and market position.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with an increase in test volumes and expansion of its service portfolio.
Thyrocare Technologies Limited announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a consolidated revenue of ₹223.95 crore for Q4 FY26, marking a 20% year-on-year growth, primarily driven by a 21% increase in the Pathology segment. Franchise revenue in the Pathology business grew by 21% year-on-year, while partnership revenue recorded a 23% year-on-year growth. The company processed 59.0 million tests in Q4 FY26, a 29% year-on-year increase, reinforcing its position as India's largest diagnostic test volume processor.
Consolidated EBITDA grew by 31% year-on-year to ₹75.09 crore, and Profit After Tax (PAT) surged by 128% year-on-year to ₹48.70 crore. The company maintained Six Sigma quality standards, reducing complaints per million tests to 3.1 (down 34% YoY) with an Average Turnaround Time (ATAT) of 3.43 hours. Thyrocare also expanded its test portfolio with advanced allergy testing and ventured into genomics with a new lab and the launch of Non-invasive Prenatal Testing (NIPT).
For the full financial year 2026 (FY26), consolidated revenue grew 21% year-on-year to ₹829.04 crore. Pathology business franchise revenue increased by 18% YoY, while partnership revenue grew by 32% YoY. Test volumes for the year reached 209.6 million, a 23% YoY growth. Consolidated EBITDA rose 38% YoY to ₹262.04 crore, and PAT grew 81% YoY to ₹162.85 crore.
Rahul Guha, MD & CEO of Thyrocare Technologies Ltd., stated, “Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India.”
What to do with a filing like this
Thyrocare Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.